Long-Term Effectiveness, Safety, and Predictive Factors of Tralokinumab Response in Adolescents with Atopic Dermatitis: Insights from a Real-World Multicenter Cohort
Tralokinumab demonstrated efficacy and safety in the treatment of moderate-to-severe AD in patients aged 12-17 years. Notably, the treatment was effective in adolescent patients with palmoplantar involvement and/or obesity.
Authors
- Tania Díaz Corpas
- Fernando Millán Parrilla
- José María Hernández (ORCID: https://orcid.org/0000-0003-1363-067X)
- Francisco Javier Melgosa Ramos (ORCID: https://orcid.org/0000-0003-2121-6727)
- Laura Berbegal de Gracia
- Pilar Villodre Lozano (ORCID: https://orcid.org/0009-0005-3922-5674)
- Montserrat Évole Buselli
- Altea Esteve Martínez
- Jérémie Pariente (ORCID: https://orcid.org/0000-0002-9850-296X)
- Javier Sánchez Arraez
Institutions
- Hospital Universitari i Politècnic La Fe (ES)
- Hospital de La Ribera (ES)
- Hospital Clínico Universitario de Valencia (ES)
- Hospital Arnau de Vilanova (ES)
- Hospital Universitario Doctor Peset (ES)
- Hospital General Universitario De Valencia (ES)
- Hospital de Sagunto (ES)
- Hospital General Universitario de Alicante Doctor Balmis (ES)
- Hospital Universitario Lluís Alcanyís (ES)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1007/s13555-025-01547-3
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00